黑色素瘤中AURKA过表达由FOXM1与MAPK/ERK激活驱动:对预后和治疗的影响
研究探讨黑色素瘤中AURKA过表达的驱动机制及其预后意义。AURKA过表达与三个独立队列的不良预后相关,并与AURKA基因座扩增及BRAFV600E突变相关;MAPK/ERK激活和FOXM1介导AURKA启动子激活,抑制AURKA和FOXM1可损害黑色素瘤生长和存活。
要点
- AURKA过表达与黑色素瘤不良预后相关,并与AURKA基因扩增和BRAFV600E突变相关。
- BRAFV600E通过MAPK/ERK信号和FOXM1驱动AURKA转录表达。
- 抑制AURKA或FOXM1在体外和体内均损害黑色素瘤生长与存活。
核心结论
- AURKA过表达由FOXM1和MAPK/ERK激活驱动,是黑色素瘤不良预后标志和潜在治疗靶点。
研究设计与样本
- 基于三个独立黑色素瘤患者队列的预后关联分析及黑色素瘤细胞系的分子机制研究。
主要发现
- AURKA过表达与三个独立队列的不良预后相关,并与AURKA基因座扩增和BRAFV600E突变相关。
- MAPK/ERK激活介导AURKA启动子激活,敲低BRAFV600E或抑制ERK降低AURKA转录和表达。
- FOXM1与AURKA表达在三个队列中正相关,FOXM1沉默降低AURKA及晚期细胞周期基因表达。
- BRAFV600E突变肿瘤中FOXM1表达显著高于BRAF野生型,敲低BRAFV600E降低FOXM1表达。
- 遗传或药物抑制AURKA和FOXM1在培养和体内均损害黑色素瘤生长与存活。
临床怎么用
- AURKA和FOXM1可作为黑色素瘤预后标志及BRAF/MEK抑制剂治疗失败患者的潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The cell cycle-related genes AURKA and FOXM1 are overexpressed in melanoma. We show here that AURKA overexpression is associated with poor prognosis in three independent cohorts of melanoma patients and correlates with the presence of genomic amplification of AURKA locus and BRAFV600E mutation. AURKA overexpression may also be driven by increased promoter activation through elements such as ETS and FOXM1 found within the 5' proximal promoter region. Activated MAPK/ERK signaling pathway mediates robust AURKA promoter activation, thereby knockdown of BRAFV600E and ERK inhibition results in reduced AURKA transcription and expression. We show a positive correlation between FOXM1 and AURKA expression in three independent cohorts of melanoma patients. FOXM1 silencing decreases expression of AURKA and late cell cycle genes in melanoma cells. We further found that FOXM1 expression levels are significantly higher in tumors carrying the BRAFV600E mutation compared with the wild-type BRAF (BRAFwt). Accordingly, the knockdown of BRAFV600E also reduces the expression of FOXM1 in BRAFV600E cells. Moreover, Aurora kinase A and FOXM1 inhibition by either genetic knockdown or pharmacologic inhibitors impair melanoma growth and survival both in culture and in vivo, underscoring their therapeutic value for melanoma patients who fail to benefit from BRAF/MEK signaling inhibition.
引用
- Puig-Butille JA, Vinyals A, Ferreres JR, et al. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy. J Invest Dermatol. 2017. PMID: 28188776. doi:10.1016/j.jid.2017.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。